Cargando…
A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
Objective: Phase I, open-label, randomized, single-dose, 3-period crossover study assessing pharmacokinetics (PK) and safety of ZX008, a liquid oral formulation of fenfluramine (FFA) under development for adjunctive treatment of Dravet syndrome and Lennox-Gastaut syndrome, administered with and with...
Autores principales: | Boyd, Brooks, Smith, Steven, Gammaitoni, Arnold, Galer, Bradley S., Farfel, Gail M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dustri-Verlag Dr. Karl Feistle
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298132/ https://www.ncbi.nlm.nih.gov/pubmed/30336805 http://dx.doi.org/10.5414/CP203276 |
Ejemplares similares
-
Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial
por: Nabbout, Rima, et al.
Publicado: (2020) -
A Phase 1, Open‐Label, Pharmacokinetic Trial to Investigate Possible Drug‐Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects
por: Morrison, Gilmour, et al.
Publicado: (2019) -
Fenfluramine HCl (Fintepla(®)) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study
por: Sullivan, Joseph, et al.
Publicado: (2020) -
Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
por: Lai, Wyman W., et al.
Publicado: (2020) -
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy
por: Ben-Menachem, Elinor, et al.
Publicado: (2020)